Health
Melanotan 1 Peptide: Understanding its Effect on Skin Cells and Cognitive Functions
Here’s what you need to know about the melanotan 1 peptide and how it affects your body.
Although much empirical data exists to allow researchers to outline and propose the properties of Melanotan 1, many studies lack clarity on the appropriate handling. The peptide was first created in the 1980s by scientists at the University of Arizona and has been studied within the context of various avenues of research, including:
- Pigmentation
- Dermatological conditions
- Sexual stimulation
Using the current research, we have created an educational guide for determining the appropriate handling of Melanotan 1. This resource also provides information on the properties and profile of Melanotan 1. Continue reading till the conclusion and supplier of research peptides, including Melanotan 1.
Melanotan 1 Peptide: What is it?
Melanotan 1 (MT1) is a manufactured peptide that may mimic the effects of alpha-melanocyte stimulating hormone (alpha-MSH), a natural hormone that may affect skin pigmentation, sexual function, food intake, and metabolism.
Studies suggest that MT1 may activate melanocytes to enhance melanin production and release by imitating alpha-MSH. Research indicates that the peptide may function by attaching itself to the melanocortin receptors 1, 3, 4, and 5 (MC1R, MC3R, MC4R, MC5R), with a strong attraction to MC1R.
The chemical was originally developed with the intention of inducing pigmentation or tanning of skin cells without exposure to UV radiation. Since its initial developmental hypothesis, investigations have purported that Melanotan 1 may have potential properties in the context of various skin illnesses and prevent cognitive decline, among other research contexts. Afamelanotide has been researched in Europe and the United States to possibly prevent sun-induced skin damage in research models of erythropoietic protoporphyria. This rare skin condition is characterized by acute non-blistering photosensitivity and intolerance to UV rays.
Melanotan 1 Peptide Potential
Research in Melanotan 1 has suggested possible advantageous impacts in several scientific contexts. Below, we address some of these topics.
Melanotan 1 Peptide and Skin Pigmentation
Research has indicated that Melanotan 1 may efficiently accelerate the tanning process while decreasing the occurrence of burning on cells via UV exposure. During three phase 1 clinical studies conducted at the Arizona Health Sciences Center, research models who were given MT1 appeared to exhibit the development of a tan without any abnormal results and with just minor effects.
Melanotan 1 Peptide and Vitiligo
In a multicenter experiment conducted in 2015, researchers aimed to ascertain if combining a Melanotan 1 implant and light therapy may provide a more productive approach for Vitiligo than phototherapy alone. After conducting a five-month study on research models of nonsegmental Vitiligo, the researchers suggested that combining MT1 with NB–UV-B phototherapy may have resulted in much better and quicker repigmentation than using either approach alone. The findings were considered statistically significant.
Melanotan 1 Peptide and EPP
Under a phase 3 clinical study including research models of erythropoietic protoporphyria (EPP), researchers investigated the impacts of Melanotan 1 under UV exposure. Research models in the EPP group who received the Melanotan 1 appeared to exhibit a substantial reduction in discomfort caused by phototoxicity, and half the number of phototoxic responses compared to those who received a placebo.
Melanotan 1 Peptide and Cognition
Scientists have used a mouse model to verify if MT1 may have the potential to delay the initiation of cognitive decline and Alzheimer’s Disease (AD). Upon presentation of the peptide, mice with mild Alzheimer’s disease (AD) suggested a decrease in the amount of amyloid beta plaques in the brain, enhancement in cognitive function and synaptic transmission, and safeguarding against neuronal death. The researchers hypothesized that the neuroprotective potential of Melanotan 1 may have been linked to its action at the melanocortin 4 receptor (MC4R).
Melanotan 1 Peptide and Skin
In 2011, German researchers ran a Phase 2 open-label trial to assess the potential impact of Melanotan 1 exposure in research models of mild to severe acne vulgaris. The study indicated that male research models who had acne on both their face and trunk appeared to have exhibited a significant reduction in inflammatory acne lesions on their faces. Additionally, as assessed by the DLQI, the exposure suggested subjective improvement.
Researchers interested in Melanotan 1 and other high-quality research compounds may buy peptides from Biotech Peptides, our recommended, reliable, and cost-appropriate online source.
References
[i] L. Mahiques-Santos, Melanotan, Actas Dermo-Sifiliográficas (English Edition), Volume 103, Issue 4, 2012, Pages 257-259 , ISSN 1578-2190,
[ii] Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006 Apr;27(4):921-30. doi: 10.1016/j.peptides.2005.01.029. Epub 2006 Jan 18. PMID: 16412534.
[iii] Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D[1]Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000 Oct;72(4):526-32. doi: 10.1562/0031- 8655(2000)072<_x0030_526:ieeati>2.0.co;2. PMID: 11045725.
[iv] Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004 Jul;140(7):827-35. doi: 10.1001/archderm.140.7.827. PMID: 15262693.
[v] Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, Skottner A. New aspects on the melanocortins and their receptors. Pharmacol Res. 2000 Nov;42(5):393-420. doi: 10.1006/phrs.2000.0725. PMID: 11023702.
[vi] Lane AM, McKay JT, Bonkovsky HL. Advances in the management of erythropoietic protoporphyria – role of afamelanotide. Appl Clin Genet. 2016 Dec 12;9:179-189. doi: 10.2147/TACG.S122030. PMID: 28003770; PMCID: PMC5161401.
[vii] Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo: A Randomized Multicenter Trial. JAMA Dermatol. 2015;151(1):42–50. doi:10.1001/jamadermatol.2014.1875
[viii] Dillon AB, Sideris A, Hadi A, Elbuluk N. Advances in Vitiligo: An Update on Medical and Surgical Treatments. J Clin Aesthet Dermatol. 2017 Jan;10(1):15-28. Epub 2017 Jan 1. PMID: 28210378; PMCID: PMC5300730.